



April, 2022

Dear SMA Community,

We want to provide an update on Biogen's work to support Ukrainian refugees, including those living with SMA.

First and foremost, Biogen stands firmly with the global community in providing humanitarian aid. Consistent with our values, Biogen and the Biogen Foundation have launched an employee-giving campaign that doubles employee's contributions to provide medical supplies, food, water, shelter and other essential support. The Biogen Foundation has also provided a \$250,000 (USD) grant to the Swiss Red Cross and Polish Humanitarian Aid, along with providing a €25,000 grant to SMA Europe. Our contributions to date have surpassed more than \$1 million in grants, in-kind materials, volunteering and other support.

We are working closely with patients, the medical community and governments to ensure people living with SMA displaced by the war in Ukraine have access to treatment across Europe. As part of the European Union Temporary Protection Directive legislation, people living with SMA who leave Ukraine can access approved and reimbursed SMA therapies and care in the European Union Member State where they register.

We are in regular communications with our partners to ensure patients continue to receive nusinersen. As of now, there is no shortage of nusinersen in the countries bordering Ukraine, and treatment continues to be available to patients. We are closely monitoring the situation for any potential supply chain disruptions that could impact patients.

Thank you for your understanding and collaboration. We remain available to answer your questions, and please don't hesitate to contact us.

Best regards,

The Biogen SMA Team